Home » Neuroprotective Agents
Product Image

Neuroprotective Agents

€123.99
Title
Quantity:
In stock with our UK publisher. 14-28 days
Delivery/Collection within 10-20 working days
14 days return policy Shipping & Delivery
aging
brain
Category=PSAN
cerebral ischemia
contributing
contributions
eq_bestseller
eq_isMigrated=1
eq_nobargain
eq_non-fiction
eq_science
events
expectancy
function
gene
heart surgery
incidence
injury
life
life expectancy
neurodegenerative diseases
neurological
particularly
range
survival
treatment
volume

Product details

  • ISBN 9781573315791
  • Weight: 708g
  • Dimensions: 155 x 229mm
  • Publication Date: 26 Jul 2006
  • Publisher: John Wiley and Sons Ltd
  • Publication City/Country: GB
  • Product Form: Paperback
Secure checkout Fast Shipping Easy returns
Description
As life expectancy has increased, so has the incidence of neurodegenerative diseases, particularly those associated with aging. Contributing to increased life expectancy is increased survival following brain injury, stroke, and procedures such as heart surgery, but these events can impair neurological function.

The wide range of contributions to this volume, from a detailed paper on the use of gene therapy in combination with hypothermia for the treatment of cerebral ischemia to a comprehensive poster describing the role of anesthetic agents in neurotoxicity during development and senescence, illustrate the scientific scope presented.

Contributions from clinical and basic science researchers from many disciplines address various approaches to providing neuroprotection. The clinical focus is on the complexity of neuroprotection, the need for understanding the time-course effects of hypoxia/ischemia, and the need for combinational and time-course applications of multiple therapies. New technologies are introduced for describing both the insult and the treatment necessary for neuroprotection, including gene expression assays (genomics) and gene therapy.

Several chapters are devoted to the examination of the predictive value of models for outcome measures in clinical ischemic stroke neuroprotective trials. The need to move from in vitro models to more predictive in vivo approaches with the use of pharmacokinetics is addressed. Other chapters emphasize the role of endogenous agents such as nitric oxide, melatonin, L-carnitine, and estrogens in acute and chronic neural injury and therapy.

NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit www.blackwellpublishing.com/nyas.

ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order (www.nyas.org). Members of the New York Academy of Science receive full-text access to the Annals online and discounts on print volumes. Please visit http://www.nyas.org/MemberCenter/Join.aspx for more information about becoming a member.
About

William Slikker Jr is the editor of Neuroprotective Agents: Seventh International Conference, Volume 1053, published by Wiley. Russell J. Andrews is the editor of Neuroprotective Agents: Seventh International Conference, Volume 1053, published by Wiley.